Drug Information

Drug General Information
Drug ID
D0W1MU
Former ID
DIB004682
Drug Name
TBC-M4
Synonyms
MVA-based HIV subtype C vaccine, IAVI; Modified vaccinia Ankara-based HIV subtype C vaccine, International AIDS Vaccine Initiative
Drug Type
Vaccine
Indication Human immunodeficiency virus infection [ICD9: 279.3; ICD10:B20-B26] Phase 1 [522665]
Company
National Institute of Cholera and Enteric Diseases
Target and Pathway
Target(s) HIV env Target Info [530544]
HIV GAG protein Target Info [530544]
Reactome Uncoating of the HIV Virion
Budding and maturation of HIV virion
Integration of provirus
Early Phase of HIV Life Cycle
Minus-strand DNA synthesis
Plus-strand DNA synthesis
2-LTR circle formation
Binding and entry of HIV virion
Membrane binding and targetting of GAG proteins
Assembly Of The HIV Virion
Integration of viral DNA into host genomic DNA
Autointegration results in viral DNA circles
APOBEC3G mediated resistance to HIV-1 infection
Vpr-mediated nuclear import of PICs
WikiPathways Host Interactions of HIV factors
HIV Life Cycle
References
Ref 522665ClinicalTrials.gov (NCT00902824) Safety and Immunogenicity of TBC-M4, a MVA HIV Vaccine Alone or in a Prime-Boost Regimen With ADVAX DNA HIV Vaccine. U.S. National Institutes of Health.
Ref 530544A Phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C-modified vaccinia Ankara virus vaccine candidate in Indian volunteers. AIDS Res Hum Retroviruses. 2009 Nov;25(11):1107-16.

If you find any error in data or bug in web service, please kindly report it to Dr. Tang and Dr. Mou.